Lantern Pharma (NASDAQ: LTRN) CEO resigns and cash falls to $7.6 million

What happened

Lantern Pharma Inc. (NASDAQ: LTRN) said CEO Panna Sharma resigned Nov. 15. CFO David Margrave is now interim CEO.

Sharma also left the board. Margrave's appointment took effect Nov. 16 and lasts until a permanent CEO is named. The board plans to start a search promptly.

The company reported third-quarter results on Nov. 18. Cash, cash equivalents and marketable securities were approximately $7.6 million at Sept. 30, down from approximately $10.1 million at Dec. 31, 2025.

Lantern said that cash is not enough to fund operations at the current level for the next 12 months. It also said there is substantial doubt about its ability to continue as a going concern without substantial additional funding.

Key numbers

Metric Latest Change Source
Cash, cash equivalents and marketable securities (Sept. 30, 2026 vs Dec. 31, 2025) $7.6 million from $10.1 million Lantern Pharma Q3 2026 earnings release (Exhibit 99.1)
Loss from operations, Q3 2026 $5.4 million from $4.3 million, +24% Lantern Pharma Q3 2026 earnings release (Exhibit 99.1)
Loss from operations excluding settlement accrual (non-GAAP), Q3 2026 $3.4 million from $4.3 million, -22% Lantern Pharma Q3 2026 earnings release (Exhibit 99.1)
Research and development expenses, Q3 2026 $1.6 million from $2.4 million, -36% Lantern Pharma Q3 2026 earnings release (Exhibit 99.1)
Gross proceeds from registered direct offering, closed Sept. 30, 2026 $4.0 million Lantern Pharma Q3 2026 earnings release (Exhibit 99.1)

Read more: Lantern Pharma (LTRN) company research

Where the quarter's loss comes from

Strip out one charge and the operating loss improved. Loss from operations was approximately $5.4 million in the third quarter, up 24% from approximately $4.3 million a year earlier. Excluding a $2.0 million accrual for the proposed settlement, it was approximately $3.4 million, down 22%. Lantern calls that excluded figure a non-GAAP measure.

Research and development expenses fell 36% to approximately $1.6 million from approximately $2.4 million a year earlier. The company cited lower research studies and materials costs tied to clinical trials. General and administrative expenses rose 99% to approximately $3.8 million from approximately $1.9 million because of the accrual. Without it, they were approximately $1.8 million, down 5%.

Net income was approximately $0.7 million, or $0.05 per basic share. A year earlier the company had a net loss of approximately $4.2 million, or $0.39 per share. The profit includes a non-cash gain of approximately $6.0 million from remeasuring warrants issued in May 2026, mainly because the stock price fell. It is not an operating gain.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

The settlement and the financing

The accrual covers a proposed settlement, reached in principle in November, with a former part-time consultant. The consultant asserted claims of disability discrimination, sexual harassment and related claims. Half is payable within 30 days of the effective date. The rest is due on the earlier of two dates: when Lantern has raised at least $10.0 million in gross cash proceeds after that date, or the two-year anniversary of the first payment.

Qualifying proceeds can come from investment, asset sales or out-licensing of company patents. The settlement is not yet final or effective, and the company says its estimate could change materially.

The September financing was a registered direct offering and concurrent private placement with an institutional investor. It closed Sept. 30 and brought in approximately $4.0 million in gross proceeds before approximately $0.4 million of offering expenses. It included 1,469,725 shares at $1.09 each, pre-funded warrants for up to 2,200,000 shares and warrants for up to 3,669,725 shares at an exercise price of $1.09.

Shares outstanding were 14,935,576 on Sept. 30 and 15,886,576 on Nov. 9. Lantern said it plans periodic capital raises, including possible sales under its ATM facility, as well as collaborations and grant funding.

Why it matters

OptimistFi has argued that Lantern is a financing-sensitive bet on whether its AI platform can produce partner-grade clinical evidence before cash burn forces dilutive capital. This filing is mixed for that view. Spending is down on a like-for-like basis, but the going-concern warning remains and the CEO seat is now interim. The company lists leadership-transition risk among its risk factors.

The clinical news is incremental. In November, the first site for the LP-184 Phase 1b/2 trial in triple-negative breast cancer completed start-up milestones and is engaged to begin enrollment. In Taiwan, the TFDA approved the amended HARMONIC protocol, and the lead site is open to accrual and screening patients. Part 2 allows LP-300 for up to eight cycles, up from six.

The evidence behind that extension is early. Patients with the L858R mutation who completed six cycles had median progression-free survival of 8.9 months. That covers nine patients, three of whom had not yet progressed. The company calls such data preliminary, exploratory and based on small patient numbers.

In glioblastoma, no objective radiographic responses were observed among 16 patients in the Phase 1a study. The planned combination trial with spironolactone depends on additional funding. That shows the tension in the case: the next evidence depends on capital Lantern has yet to raise.

What's next

Lantern expects IRB approval at two more Taiwan sites in the fourth quarter of 2026. Those approvals would move more sites toward opening for HARMONIC Part 2. Missing that timing would weaken the case for steady trial progress.

The settlement is the other dated item. Once it is effective, the first payment is due within 30 days. A raise that reaches the threshold above would bring the second payment forward. A further capital raise, under the ATM facility or otherwise, would test the dilution side of the case.

The interim period ends when the board appoints a permanent CEO.

More from OptimistFi

From OptimistFi Perps

Sources

Explore OptimistFi research on Lantern Pharma Inc.: https://optimistfi.com/stocks/LTRN

Browse Lantern Pharma Inc. company coverage and explore the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

Find available research on the Lantern Pharma Inc. company page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.